Inactive HBsAg Carriers (IHCs) Treated With Pegylated Interferon α2b Based Intervention Therapy
Status:
Completed
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
A single center, randomized controlled trial design was used to select patients with chronic
hepatitis B in the immune control period (i.e. HBsAg positive, HBeAg negative, normal ALT,
HBsAg ≤ 1500iu/ml, HBV DNA ≤ 2000iu/ml) to enter the study, and to compare the feasibility,
effectiveness and safety of pegylate combined with Granulocyte-macrophage colony stimulating
factor, high-dose hepatitis B vaccine and pegylate monotherapy in the treatment of patients
with chronic hepatitis B in the immune control period